Please login to the form below

Not currently logged in

IMS Health acquired in $5.2bn deal

IMS Health is to be acquired by TPG Capital and the CPP Investment Board in a transaction worth $5.2bn

IMS Health, who provide market intelligence to the pharmaceutical and healthcare industries, is to be acquired by TPG Capital and the CPP Investment Board (CPPIB) in a transaction worth $5.2bn including the assumption of debt.

The deal will see IMS shareholders receive $22 per share – around 50 per cent over the closing price.

"This transaction enables our shareholders to realise substantial value from their investment in IMS with an immediate cash premium, while at the same time strengthening our position to capture long-term growth opportunities," said IMS chairman and CEO David R Carlucci.

"With the backing of world-class private equity partners, we will continue our focus on expanding into new markets, further improving the quality and depth of offerings we deliver to our clients, and playing a bigger role in the healthcare market," Carlucci added.

The IMS board of directors unanimously approved the agreement. They took guidance from a specialist committee who were established to review IMS' strategic alternatives. The transaction includes fully committed financing. This is made up of equity investments from TPG and CPPIB and debt financing provided by affiliates such as Goldman Sachs & Co.

The deal is subject to approval from IMS shareholders and regulatory and customary closing conditions. It is expected to complete by the end of Q1 2010.

5th November 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...